Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
60 Degrees Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapies for rare diseases, particularly in the area of infectious diseases. The company is distinguished by its proprietary drug delivery technology, which enhances the efficacy and safety of its treatments, primarily targeting markets in North America and Europe.
60 Degrees Pharmaceuticals generates revenue through the sale of its proprietary therapies, leveraging its unique drug delivery technology to command premium pricing. The company benefits from a low debt-to-equity ratio, allowing it to invest in R&D while maintaining financial flexibility.
Regulatory approvals for new therapies
Partnership agreements with larger pharmaceutical companies
Clinical trial results impacting product efficacy
Market expansion into new geographies
Regulatory changes impacting drug approval processes
Technological disruption in drug delivery methods
Emergence of generic alternatives to proprietary therapies
Increased competition from larger biotech firms with more resources
High operating losses leading to cash burn
Dependence on successful fundraising for ongoing R&D
moderate - The demand for healthcare products can be resilient during economic downturns, but funding for R&D may be affected by broader economic conditions.
Interest rates affect the company primarily through the cost of capital for funding R&D initiatives. Higher rates could constrain investment in new product development.
minimal - The company has a low debt-to-equity ratio, reducing its reliance on credit markets.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has demonstrated significant volatility, particularly given its recent performance metrics.
